Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy

Yonsei Medical Journal

Volumn 50, Issue 3, 2009, Pages 437-440

  Choi, Won Hyuk ^a   Kim, Sungsoo ^a   Hyung, Woo Jin ^a   Yu, Jeong Sik ^a   Park, Chan Il ^a   Choi, Seung Ho ^a   Noh, Sung Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cytoreductive surgery; Gastrointestinal stromal tumors; Imatinib; Recurrence

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DUODENUM BIOPSY; DUODENUM ULCER; EPIGASTRIC PAIN; ESOPHAGOGASTRODUODENOSCOPY; GASTRECTOMY; GASTRODUODENOSTOMY; GASTROINTESTINAL STROMAL TUMOR; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LAPAROSCOPIC SURGERY; LIVER METASTASIS; MALE; MELENA; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOFREQUENCY ABLATION; SURVIVAL TIME;

GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 67651165286     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2009.50.3.437     Document Type: Article

References (17)

1. Gold JS, Dematteo RP. combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006;244: 176-84.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-78.
3. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38:S83-7.
4. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32.
5. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-34.
6. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5.
7. Ballarini C, Intra M, Ceretti AP, Prestipino F, Bianchi FM, Sparacio F, et al. Gastrointestinal stromal tumors: a "benign" tumor with hepatic metastasis after 11 years. Tumori 1998;84:78-81.
8. Miettinen M, El-Rifai W, H L Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-83.
9. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294-9.
10. Chen LL, Sabripour M, Andtbacka RH, Petel SR, Feig BW, Macapinlac HA, et al. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 2005;7:293-9.
11. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128: 270-9.
12. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005;103:821-9.
13. Tryggvason G, Gislason HG, Magnússon MK, Jónasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005;117:289-93.
14. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64.
15. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and Safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
16. Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007;14:526-32.
17. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.